New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by 
Ventana to create a companion diagnostic for Millennium/Seattle Genetics' Adcetris
Apr 2012
Executive Summary
Roche’s cancer diagnostics division Ventana Medical Systems Inc. has agreed to develop, manufacture, and sell a molecular companion diagnostic that would be used in the treatment planning for Adcetris (brentuximab vedotin), a lymphoma therapy developed by Seattle Genetics Inc. and Millennium: The Takeda Oncology Co.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ventana to create a companion diagnostic for Millennium/Seattle Genetics' Adcetris
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice